Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 2 sources

Mechanistic classification

“ABL001 (NOV1501/TR009), a bispecific antibody targeting VEGF and DLL4, is being developed as an anti-angiogenic cancer therapeutic that strengthens the effects of VEGF inhibitors and eventually overcomes resistance to anti-VEGF therapy” (opens the source at this quote in a new tab)

“Targeting DLL4 expression may be a feasible approach to interfere with angiogenesis, tumorigenesis, and metastasis for anti-cancer effect” (opens the source at this quote in a new tab)

AHFS classification or ATC code

No evidence found.